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Introduction
The prevalence of obesity has increased dramatically as a result 
of modern lifestyles, and is now one of the most important targets 
of public health programmes.1 Paediatric obesity is a complex and 
growing global problem. In Egypt, the prevalence of obesity among 
school children was found to be 14.7% among boys, and 15.08% 
among girls.2 Childhood obesity increases the risk of obesity in 
adulthood, and is associated with cardiovascular disease risk 
factors, such as hypertension, diabetes mellitus and dyslipidemia.3
In 1988, Reaven et al described “the metabolic syndrome” (MS) as 
a link between insulin resistance and hypertension, dyslipidaemia, 
type 2 diabetes, and other metabolic abnormalities associated 
with an increased risk of atherosclerotic cardiovascular disease in 
adults.4 However, nowadays, this problem is observed with even 
greater frequency among children, particularly those with excess 
body mass. Identification of causes or aetiological factors for the 
development of MS is important, so that suitable measures can be 
instituted to prevent and cure the syndrome.5
Although the underlying pathophysiology of MS is unclear, insulin 
resistance is thought to be a central abnormality in the pathogenesis 
of the disorder.6 Recent studies suggest that, besides insulin 
resistance, the adipocyte-derived hormone adiponectin may be 
an important predictive marker for MS.7 Adiponectin is the most 
abundantly expressed adipokine in adipose tissue.8 Adiponectin is 
a multifunctional protein that exerts pleiotropic insulin-sensitising 
effects. It reduces hepatic glucose production,9 and increases glucose 
uptake and fatty acid oxidation in skeletal muscle.10 Moreover, 
adiponectin may possess anti-atherogenic properties by inhibiting 
the expression of adhesion molecules and smooth muscle cell 
proliferation, as well as suppressing the conversion of macrophages 
to foam cells.11 An anti-inflammatory role of adiponectin has also 
been reported.12
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Objectives: The objectives were to investigate the relationship between the serum adiponectin level and the metabolic syndrome (MS) 
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Low plasma adiponectin levels are predictive of insulin resistance 
and type 2 diabetes in adults.13 Children with type 2 diabetes have 
significantly lower adiponectin levels than their normoglycemic 
counterparts.14 Thus, it is thought that low levels of circulating 
adiponectin may be an early marker of metabolic disease risk 
in children. To date, limited investigations have examined the 
associations between adiponectin and MS in children. Because 
adiponectin is related to, and may be contributory to, the 
development of insulin resistance and the MS, investigations 
examining the independent associations may offer further insights 
into the pathways mediating obesity and chronic disease in children.
The overall objective of this study was to investigate the relationship 
between the serum adiponectin level and the MS phenotype in 
children. The secondary objective was to examine the independent 
association between the serum adiponectin level and the individual 
components of MS.
Method
A cross-sectional study was carried out among children aged 10-12 
years in 14 primary schools (government and private schools) in an 
urban area of the city of Ismailia, Egypt. The multi-stage stratified 
cluster random sampling method was applied. The prevalence of 
obesity and overweight was 13.6%. A simple random sample was 
used. A list of all obese children was compiled, from which 56 
obese children were eventually included. (Printed tables of random 
numbers were used). 
Children were eligible for inclusion in the study if their body mass 
index (BMI) was ≥ 95th Egyptian percentile for age and sex for the 
obese group, and if they had a BMI between the 25th-75th percentiles 
for age and sex for the control group. Recently developed Egyptian 
BMI percentile charts were used.15 Exclusion criteria were the 
presence of any cardiac, renal, rheumatic, metabolic, or endocrine 
disease. The control group included 56 normal-weight children, 
matched for age and sex with the obese children. Six of control 
group refused blood sampling. 
The following investigations were carried out, and measurements 
taken, for each participating child: 
A complete medical history and physical examination.
•	 Anthropometric	 measurements: Height was measured to the 
nearest centimetre using a rigid stadiometer, and weight was 
measured to the nearest 0.1 kg using a calibrated balance scale. 
BMI was calculated as weight in kilogrammes divided by the 
height in meters squared. Waist circumference was measured 
at the level of the umbilicus, at the end of normal expiration.16 
We included children whose waist circumference was ≥ 90th 
percentile for age and sex.
•	 Blood	 pressure	measurements: Blood pressure was measured 
by the auscultatory method, using a sphygmomanometer with a 
suitable cuff size. Three readings were taken while the subjects 
were seated, and the last two measurements were averaged for 
analysis.
•	 Blood	investigations: A blood sample was collected from each child 
in the morning after an overnight fast to measure fasting blood 
glucose, high-density lipoprotein (HDL) cholesterol, triglycerides 
(TGs) and adiponectin. Serum glucose, HDL cholesterol and TGs 
were measured by standard enzymatic methods (Boehringer 
Mannheim reagents), using a fully automated analyser (Behring® 
RXL autoanalyser, Germany). Serum adiponectin was determined 
with an enzyme immunoassay (human adiponectin ELISA Kit®, 
B-Bridge International, California, USA). 
The definition of MS applied in this study was defined according to 
the latest International Diabetes Federation consensus definition of 
MS in children and adolescents.17 According to this definition, MS is 
considered to be present in the age group 10 to < 16 years if there is 
abdominal obesity (waist circumference ≥ 90th percentile for age and 
sex), and the presence of two or more other features among these 
four parameters: elevated TGs (≥ 150 mg/dl), low HDL cholesterol 
(< 40 mg/dl), elevated blood pressure (systolic blood pressure 
≥ 130 mm Hg, or diastolic blood pressure ≥ 85 mm Hg), and impaired 
fasting glycaemia (glucose ≥ 100 mg/dl). 
Statistical analysis
The data were analysed using the statistical package, SPSS®. 
Descriptive statistics were used to present the characteristics of the 
study population. Continuous data were compared using Student’s 
t test. Pearson’s correlation coefficient was used to establish the 
association between plasma adiponectin concentrations and the 
clinical parameters of MS. A logistic regression analysis was used to 
assess the independent association between the serum adiponectin 
level, and the individual components of MS. Statistical significance 
was considered to be p-value < 0.05. 
Results
The characteristics of the study population are tabulated in Table I. 
There was no significant difference between the two groups regarding 
the age and sex. The mean BMI percentile was significantly higher 
in the obese group (97.4 ± 1.8), than in the control group (51.8 
± 18.6). The mean serum adiponectin level was significantly lower 
in the obese group, compared to the control group. The prevalence 
of MS among the obese children was 44.6%.
Table I: Characteristics of the study population
Obese children Control p-value
Number of subjects 56 50 0.213
Age (years) 11.1 ± 0.9 10.9 ± 1.1 0.513
Sex
Female 31 28
Male 25 22 0.372
Weight (kg) 61.7 ± 7.8 34.7 ± 8.9 0.005a
Body mass index 28.4 ± 2.2 18.2 ± 3.9 0.009a
Body mass index percentile 97.4 ± 0.8 51.8 ± 18.6 0.009a
Waist circumference (cm) 83.5 ± 5.3 62.3 ± 9.4 0.01a
Adiponectin level (µg/ml) 7.35 ± 3.1 10.64 ± 3.04 0.03a
Values are mean ± standard deviation 
a = significant difference
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Table II shows the comparison between obese children with and 
without MS, according to the distribution of the individual criteria of 
diagnosis. There was a statistically significant difference between 
the obese children with and without MS, regarding the presence of 
all individual components of the syndrome. The serum adiponectin 
level was significantly lower in obese children with MS (5.92 ± 1.9) 
µg/ml, compared to those without MS (8.57 ± 2.1) µg/ml. 
To control for the confounding effect of age and sex on the relationship 
between adiponectin level and MS, a logistic regression model was 
used (Table III). The dependent variable was the presence of MS, and 
the independent variables were age, sex and the serum adiponectin 
level. The serum adiponectin level remained a significant predictor of 
MS. There was a significant negative correlation between the serum 
adiponectin level and waist circumference, TG levels, systolic blood 
pressure, diastolic blood pressure and fasting blood glucose. 
Table III: Independent association of different variables with the metabolic 
syndrome
Variable Odds ratio 95% CIa
Age 0.55 0.39-1.31
Sex 0.49 0.25-1.22
Body mass index 0.79 0.65-0.94b
Adiponectin 0.76 0.63-0.91b
a = confidence interval, b =significant difference
The serum adiponectin level correlated positively with the level of 
HDL cholesterol (Table IV).
Table IV: Correlation coefficients of the relationships between adiponectin 




Waist circumference -0.33 0.000a
Triglyceride levels -0.35 0.000a
High-density lipoprotein cholesterol 0.21 0.009a
Systolic blood pressure -0.23 0.004a
Diastolic blood pressure -0.22 0.006a
Fasting plasma glucose -0.24 0.001a
a = significant difference
Using stepwise multiple linear regression 
analysis, adiponectin as the dependent 
factor, and age, sex, waist circumference 
and BMI as independent factors, waist 
circumference and BMI were significant 
determinants of adiponectin; p-value 
< 0 .0001 and 0.001, respectively.
Discussion
The MS is a cluster of interrelated risk 
factors that increases an individual’s 
susceptibility to cardiovascular morbidity 
and mortality.18 In this study, the 
prevalence of MS in obese children was 
found to be 44.6%. Different prevalence rates of MS among obese 
children have been reported in different studies. Zeitoun et al19 
carried out a study in Egypt, and reported a prevalence rate of 53.6% 
among obese children. In England, the prevalence was reported to 
be 33%.20 In Mexico, MS was present in 35% of obese children.21 In 
France, 42.5% of obese children were reported to have MS.22 The 
difference between the prevalence rates of MS between studies 
can be explained by the difference in the definitions used for the 
MS components. The present study addresses the issue in obese 
Egyptian children. Currently, there are no unified criteria available for 
the diagnosis of MS in children.23 Furthermore, differences between 
different countries may imply differences in ethnic susceptibility.24 
Regarding the adiponectin level, the results of our study showed 
that obese children have a significantly lower adiponectin level, 
compared to normal weight controls. Furthermore, obese children 
with MS have a significantly lower adiponectin level compared to 
obese children without MS. After controlling for the confounding 
effect of age, sex and central obesity, the adiponectin level remained 
a significant predictor of MS. Waist circumference was used as 
an indicator of central obesity, as it has been found to be a good 
indicator of this.25
Our results are in agreement with those of Shaibi et al,26 who 
demonstrated that adiponectin levels are approximately 25% 
higher in healthy obese children, compared to those with MS. 
Furthermore, Valle et al27 demonstrated that obese children with MS 
have a significantly lower adiponectin level, compared to non-obese 
children. Similarly, Weiss et al28 demonstrated that obese children 
with MS have a significantly lower adiponectin level, and that 
adiponectin levels decreased with increasing obesity. Adiponectin 
levels were approximately 25% higher in healthy overweight youth, 
compared with those with MS (12.5 ± 3.5 vs. 9.4 ± 2.8 μg/ml; 
p-value	< 0.05). 
Our results demonstrated that the adiponectin level correlated with 
all the individual parameters of MS. There was a significant negative 
correlation between adiponectin level and waist circumference, 
TG levels, systolic blood pressure, diastolic blood pressure, and 
fasting blood glucose. The adiponectin level correlated positively 
with the level of HDL cholesterol. These results are in agreement 
Table II: Distribution of individual parameters of the metabolic syndrome and adiponectin among obese 
children
Obese with MSa (25)
Number (%)
Obese without MS (31)
Number (%)
p-value
Waist circumference ≥ 90th percentile 25 (100) 20 (64.5) 0.001b
Body mass index 28.30 27.97 0.02
Triglycerides ≥ 150 mg/dl 16 (64) 3 (9.7) 0.000b
High-density lipoprotein cholesterol 
< 40 mg/dl
20 (80) 18 (58.1) 0.013b
Hypertension 6 (24) 2 (6.5) 0.001b
Fasting glucose ≥ 100 mg/dl 5 (20) 1 (3.2) 0.001b
Adiponectin level (µg/ml) 5.92 ± 1.9 8.57 ± 2.1 0.04b
a = metabolic syndrome, b = significant difference
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the findings of Shaibi et al,26 who demonstrated that adiponectin 
was significantly and inversely related to systolic blood pressure, 
waist circumference, triglycerides and two-hour glucose levels, and 
positively related to HDL cholesterol, independent of age, sex, body 
composition and insulin sensitivity. Winer et al29 showed that a low 
level of adiponectin is associated with components of MS, such as 
low HDL cholesterol, and a high TG:high-density lipoprotein ratio. 
Saltevo et al30 reported similar results for adults. He demonstrated 
that the adiponectin level linearly correlates with the components 
of MS. 
The molecular basis of MS has not been fully elucidated yet. One 
important explanation relates to the role of adipose tissue. Adipose 
tissue is not merely a simple reservoir of energy stored as TGs. It 
also serves as an active secretory organ, releasing many peptides, 
complement factors, and cytokines into the circulation.31 In the 
presence of obesity, the balance between these numerous molecules 
is altered, such that enlarged adipocytes and macrophages embedded 
within them produce fewer anti-inflammatory peptides, such as 
adiponectin. The dysregulated production of adipocytokines has been 
found to be implicated in the development of metabolic and vascular 
diseases related to obesity.32 Adiponectin, as an adipose-derived 
protein, has multiple functions, including anti-atherogenic, insulin 
sensitising, lipid-oxidation enhancing, and vasodilatory activities.33 
Therefore, it is possible that decreased plasma concentrations of 
adiponectin play a significant role in the development of MS. 
The lack of pubertal status or Tanner staging assignment is 
an important limitation to our study. The study did not allow 
for establishing a cause-and-effect relationship, and requires 
confirmation by prospective studies.
Conclusion
In conclusion, the adiponectin level is well associated with MS. 
In particular, adiponectin demonstrated a consistent relation to 
each MS component. The present results raise the possibility that 
adiponectin is a substantial key molecule in the development of MS, 
and may be a comprehensive marker of the MS condition. Further 
prospective studies are warranted to confirm these findings. If 
confirmed, measures to increase circulating adiponectin might be 
crucial for the prevention or management of MS. 
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